CMO Collins exercised options and sold 5,000 shares for $263K at $52.67, just 2.7% below the 90-day high. This is a routine exercise-and-sell transaction with no change to her existing holdings, consistent with her pattern of nine prior sales.

Where it could go — Our 1-4 conviction officer sells: 59% beat SPY at 30d with avg +3.3% vs SPY.

CFO Hohl Benjamin sold $317K worth of ELVN shares, reducing his direct holdings by 11.6% at a price just 2.7% below the 90-day high. This appears to be routine diversification given his consistent selling pattern and lack of other insider buyers in recent months.

Where it could go — Our 1-4 conviction officer sells: 59% beat SPY at 30d with average +3.3% outperformance; watch $54.10 as resistance, $42.22 as support.

Director Kunkel sold $505K of ELVN shares, reducing her directly held stake by 19.3% while the stock traded just 3.6% below its 90-day high. This second substantial sale in a month suggests ongoing insider distribution despite the stock's strong recent performance.

Where it could go — Our 1-4 conviction sell signals: 55% beat SPY at 30d (n=1075, avg +1.6% vs SPY); watch $52.39 as resistance, $48.00 as support break.

The life sciences investment firm OrbiMed Advisors reduced its direct position in ELVN by $39.0M, selling 11.6% of its directly held shares at $45.36, a price 54% above the 90-day low. This is the firm's second multi-million dollar sale of ELVN shares within seven days, following a $12.7M transaction, despite a 'Strong Buy' consensus from 17 analysts.

Where it could go — Large-scale venture capital exits are often neutral for stock direction; watch for a potential secondary offering or for the selling pressure to subside.

CMO Collins exercised 5,000 options and immediately sold them for $219K at $43.80, maintaining her existing stake unchanged. This appears to be a routine transaction following her established pattern of option exercises and sales, not a meaningful change in her position.

Where it could go — 5 similar ELVN signals averaged +13.8% at 30d; watch $48.53 as the bull trigger, $33.45 as the bear break.

CFO Hohl Benjamin exercised options and sold 6,018 shares for $264K at $43.80, maintaining his existing position unchanged. This represents his 20th sale on ELVN and follows a predictable pattern of option monetization rather than meaningful position reduction.

Where it could go — 4 similar ELVN signals averaged +13.8% at 30d; broad universe shows 41.7% positive at 90d.

Healthcare-focused investment firm OrbiMed Advisors sold $12.7M of ELVN shares, reducing their direct holdings by 3.7% at $45.02 per share. This marks their first-ever sale in ELVN despite maintaining a substantial position and strong analyst consensus of 16 buy ratings.

Where it could go — First sales by major biotech investors → neutral signal when position remains large; watch for additional filings to confirm exit pattern.

Director Lori Kunkel sold $345,000 worth of shares, reducing her stake by 16.2% at a price 29% below the 90-day high. This first-ever sale after a 15-year tenure is a notable change in behavior, but its bearish signal is isolated against a backdrop of no other insider sellers and strong analyst support.

Where it could go — Analyst mean target not provided; bear case if stock breaks below the recent 90-day low of $26.70.

Collins Helen Louise exercised 5,000 options at $2.48 and sold the resulting shares at $39.53 ($137K). The sale came from newly exercised options and did not reduce previously held shares, leaving 26,525 directly held shares.

Where it could go — Exercise-and-sell transactions are largely mechanical and carry limited directional signal.